| Ticker: HPIP | 3550 General Atomics Court | |
| Exchange: NASDAQ-National Market | San Diego, California 92121 | |
| Industry: Service | (619) 455-3814 |
| Type of Shares: | Common Shares | Filing Date: | 2/14/96 | |
| U.S. Shares: | 3,300,000 | Offer Date: | 3/29/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 3,300,000 | Offer Price: | $8.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.56 | |
| Offering Amount: | $39,600,000 | Selling: | $0.32 | |
| Expenses: | $600,000 | Reallowance: | $0.10 | |
| Shares Out After: | 12,591,386 |
| Manager | Tier | Phone |
| Dillon, Read & Co. Inc. | Lead Manager | (212) 906-7000 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 576-3423 |
| Salomon Brothers Inc. | Co-manager | (212) 783-2947 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $1.37 | Assets: | $2.75 | ||
| Net Income: | -$9.49 | Liabilities: | $4.35 | ||
| EPS: | -$1.05 | Equity: | -$1.60 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company utilizes combinatorial chemistry to pursue the discovery of novel, small molecule drug therapies. Combinatorial chemistry is a technology for the synthesis, identification and optimization of lead compounds that can significantly shorten the time required for, and reduce the costs associated with, drug discovery. HPI currently has nine external discovery collaborations covering 19 molecule targets. HPI has used its molecule diversity tools in internal programs to discover a series of proprietary compounds, the most advanced of which is presently in a Phase II clinical trial. A critical goal for pharmaceutical companies is the rapid and cost effective discovery, development and commercialization of new compounds to treat human diseases. Conventional methods of identifying lead drug candidates have proven costly and time consuming. Combinatorial chemistry directly addresses these inefficiencies present in the traditional drug discovery process. |
| Use of Proceeds |
| Proceeds from the proposed offering will be used for research and development expenses, the redemption of the company's Series One Redeemable Preferred Stock and general corporate purposes including working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.